Trials / Completed
CompletedNCT02549664
Exercise in Genetic Cardiovascular Conditions
Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy "LIVE-HCM"/Lifestyle and Exercise in the Long QT Syndrome "LIVE-LQTS"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,299 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 8 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The goal is to determine how lifestyle and exercise impact the well-being of individuals with hypertrophic cardiomyopathy (HCM) and long QT syndrome (LQTS). Ancillary study Aim: To understand how the coronavirus epidemic is impacting psychological health and quality of life in the LIVE population
Detailed description
Yale is the central site for this multicenter study. Patients with HCM and LQTS will be recruited via high-volume HCM and LQTS sites, patient-groups, and websites. Information about exercise participation will be acquired via interview and online instruments at enrollment and every six months for three years. Quality of Life questionnaires will be filled out at enrollment and at the end of the study. Participants will receive a Fitbit (pedometer) and will wear it initially for two weeks and then one week every three months. The Fitbit is used for assessment of exercise level only. Clinical records will be obtained from treating physicians. Participants will also be asked to call the central site if they experience syncope, appropriate ICD (implantable cardioverter defibrillator) shock, or resuscitated arrest. Information regarding the patient's activity at the time of event will then be obtained by phone interview. Follow-up clinical records will be obtained as indicated to corroborate endpoints. The Ancillary study is optional. This will include all of the baseline questionnaires,as well as selected questions from the Epi-Pandemic Impacts Inventory.
Conditions
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2022-11-14
- Completion
- 2022-11-14
- First posted
- 2015-09-15
- Last updated
- 2023-09-05
Locations
36 sites across 5 countries: United States, Australia, Canada, New Zealand, United Kingdom
Source: ClinicalTrials.gov record NCT02549664. Inclusion in this directory is not an endorsement.